Impact of inhaled nitric oxide therapy in patients with cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation combined with Impella: a retrospective cohort study
Authors' conclusion
iNO therapy in patients with CS requiring ECPELLA was associated with short-term prognosis by improving RV function and facilitating weaning from VA-ECMO.
Study context
- Population
- Consecutive patients with cardiogenic shock supported by veno-arterial extracorporeal membrane oxygenation (VA-ECMO) combined with Impella (ECPELLA), September 2019 to March 2024
- Participants
- 48 patients
- Exposure
- Inhaled nitric oxide (iNO) therapy vs no iNO therapy in ECPELLA patients
- iNOn = 25
- Outcome
- 30-day survival
- Follow-up
- 30 days
Methodological detailssingle-centre, consecutive patients
- Single-centre
- Consecutive patients
Main finding
As reported in the abstract
P = 0.0002
Observational data: associations, not effects.
Further findings
VA-ECMO withdrawal rate
P = 0.002
Time to VA-ECMO withdrawal · spread printed in brackets, kind not named
P = 0.0008
Pulmonary artery pulsatility index (PAPi) and Impella flow over time
- Significant improvements in PAPi over time and a trend toward increased Impella flow with iNO
Original publication
Impact of inhaled nitric oxide therapy in patients with cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation combined with Impella: a retrospective cohort study. J Intensive Care. Published 18 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →